TELYF (TelyRx Holdings) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TELYF TelyRx Holdings Inc TELYF
12 GF Score
Price $1.88
! 2 Warning Signs
View Full Analysis

What is TelyRx Holdings 3-Year EBITDA Growth Rate?

TelyRx Holdings TELYF +1.62% 12 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates TELYF with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 526 Healthcare Providers & Services companies, TelyRx Holdings ranks worse than 190113.88% on this metric.

TelyRx Holdings's EBITDA per Share for the three months ended in Jun. 2026 was $-0.16.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

TelyRx Holdings  (OTCPK:TELYF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

TelyRx Holdings 3-Year EBITDA Growth Rate Related Terms

TELYF vs : 3-Year EBITDA Growth Rate Comparison

For the Pharmaceutical Retailers subindustry, TelyRx Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TelyRx Holdings 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TelyRx Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where TelyRx Holdings's 3-Year EBITDA Growth Rate falls into.


TELYF
12GF Score
TelyRx Holdings Inc TELYF
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TelyRx Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
TelyRx Holdings (TELYF) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for TelyRx Holdings and its competitors. According to the industry distribution chart, TelyRx Holdings ranks #999999 out of 526 companies in the Healthcare Providers & Services industry.
Is TelyRx Holdings' 3-Year EBITDA Growth Rate too high?
TelyRx Holdings' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, TelyRx Holdings ranks #999999 out of 526 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' 3-Year EBITDA Growth Rate compare to ?
According to the Healthcare Providers & Services industry distribution chart, TelyRx Holdings ranks #999999 out of 526 companies for 3-Year EBITDA Growth Rate. This places TelyRx Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for TelyRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TelyRx Holdings's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TELYF) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. TelyRx Holdings' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For TelyRx Holdings (TELYF), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TelyRx Holdings Business Description

Comparable Companies
Other Exchanges TELY:Canada
Address 24761 US Highway 19 North, Clearwater, FL, USA, 33763
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score

Get the complete analysis for TELYF

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.88
Price